Table 14 Important studies concerning the treatment of sfM
From: Results of interventional treatment of peripheral slow-flow malformations
Author | Publication date | sfMs type | Number of patients | Sclerosing agent | Location |
|---|---|---|---|---|---|
van der Linden et al | 2009 | VMs | 66 | Polidocanol Ethanol | all peripheral VMs |
Zhan et al | 2020 | VMs | 38 | Polidocanol | peripheral limb VMs |
Nakamura et al | 2014 | VMs | 40 | Polidocanol Ethanol EO | peripheral limb VMs |
Gorman et al | 2018 | VMs | 34 | Ethanol STS | all peripheral VMs |
Teusch et al | 2016 | VMs | 31 | Ethanol | all peripheral VMs |
Nevesny et al | 2021 | VMs, LMs | 26 | Bleomycin | all peripheral VMs |
Clemens et al | 2017 | VMs | 77 | Ethanol STS | all peripheral VMs |
Lee et al | 2003 | sfMs and hfMs | 87 | Ethanol | all peripheral VMs |